ERBB2 and breast carcinoma: The Prosigna assay centred on the PAM50 gene signature was developed to identify intrinsic breast cancer subtypes (luminal A/B, HER2 enriched, basal like) and a risk of recurrence (ROR) score that correlates with the probability of distant recurrences [26], [27].